Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company
with a portfolio of innovative, clinical stage product candidates for viral
diseases and cancer, today announced financial results for the second quarter
of fiscal year 2006 ended October 31, 2005. The company reported a consolidated
net loss of $4,571,000, or $0.03 per basic and diluted share, compared to $3,638,000,
or $0.03 per basic and diluted share, for the prior year period.